Using DNA Methylation to Predict Survival After Lung Cancer Surgery
A Multicenter Retrospective Study Identifying DNA 5mC Predictors for LUAD Prognosis
Nanjing University · NCT06477211
This study is trying to see if changes in DNA from lung cancer samples can help predict how long patients will survive after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Sex | All |
| Sponsor | Nanjing University (other) |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06477211 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess DNA methylation modifications in lung adenocarcinoma samples to develop a prognostic model for predicting survival outcomes after surgery. By analyzing DNA 5-methylcytosine levels in cancer tissues, the study will link these profiles to post-surgical recurrence and survival rates. Conducted across two hospitals in China, it will utilize over three years of clinical data to validate the model's accuracy and explore its potential in guiding adjuvant treatment strategies for high-risk patients. The ultimate goal is to enhance personalized treatment planning for lung adenocarcinoma patients.
Who should consider this trial
Good fit: Ideal candidates include patients with histologically confirmed early-stage lung adenocarcinoma who have undergone surgical treatment.
Not a fit: Patients diagnosed with other serious illnesses or those who have received prior treatments before surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for predicting survival outcomes and tailoring treatment strategies for lung adenocarcinoma patients.
How similar studies have performed: Other studies have shown promise in using DNA methylation profiles for cancer prognosis, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed early-stage lung adenocarcinoma, or clinically diagnosed early-stage lung adenocarcinoma. * Underwent surgical treatment * Cancer tissues well paraffin-embedded or cryopreserved Exclusion Criteria: * Diagnosed with other serious illnesses * Received other treatments before surgery * Surgery to remove multiple cancerous tissues
Where this trial is running
Nanjing, Jiangsu
- Nanjing Drum Tower hospital — Nanjing, Jiangsu, China (RECRUITING)
Study contacts
- Principal investigator: Qihan Chen, PhD — Nanjing University
- Study coordinator: Qihan Chen, PhD
- Email: chenqihan@nju.edu.cn
- Phone: +8613236592587
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Adenocarcinoma, Surgery, Prognostic Cancer Model, DNA methylation, prognosis, LUAD